Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1151 to 1200 of 1379 results for patients and public

  1. Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]

    In development [GID-HST10055] Expected publication date: 29 January 2025

    Highly specialised technologies guidance
    In development

  2. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    In development [GID-TA11255] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146

    Awaiting development [GID-TA11222] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development [GID-TA11161] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Unilateral MRI-guided focused ultrasound thalamotomy for moderate-to-severe tremor in Parkinson's disease

    Awaiting development [GID-IPG10375] Expected publication date: 12 December 2024

    Interventional procedures guidance
    Awaiting development

  6. MRI guided focused ultrasound subthalamotomy in parkinson's disease

    Awaiting development [GID-IPG10402] Expected publication date: 12 December 2024

    Interventional procedures guidance
    Awaiting development

  7. Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]

    In development [GID-TA11174] Expected publication date: 16 October 2024

    Technology appraisal guidance
    In development

  8. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]

    In development [GID-TA10784] Expected publication date: 16 October 2024

    Technology appraisal guidance
    In development

  9. Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990

    Awaiting development [GID-TA11519] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]

    Awaiting development [GID-TA11115] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]

    In development [GID-TA11148] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  12. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    Awaiting development [GID-TA11365] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    In development [GID-TA11215] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development [GID-TA10858] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. ONS-5010 for treating wet age-related macular degeneration ID6320

    In development [GID-TA11193] Expected publication date: TBC

    Technology appraisal guidance
    In development

  16. Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

    In development [GID-HST10060] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  17. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    In development [GID-TA11199] Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Pegcetacoplan for treating geographic atrophy [ID4041]

    In development [GID-TA11351] Expected publication date: TBC

    Technology appraisal guidance
    In development

  19. Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

    In development [GID-TA11298] Expected publication date: TBC

    Technology appraisal guidance
    In development

  20. Burosumab for treating X-linked hypophosphataemia in adults [ID3822]

    In development [GID-TA10733] Expected publication date: TBC

    Technology appraisal guidance
    In development

  21. Sipavibart for preventing COVID-19 [ID6282]

    In development [GID-TA11352] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  22. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development [GID-TA11228] Expected publication date: 25 September 2024

    Technology appraisal guidance
    In development

  23. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212

    In development [GID-TA11203] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  24. Cladribine for treating relapsing multiple sclerosis ID6263

    In development [GID-TA11293] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  25. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development [GID-HST10054] Expected publication date: 30 October 2024

    Highly specialised technologies guidance
    In development

  26. Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

    In development [GID-TA10165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  27. Topical Antimicrobial dressings for wound care: Late stage assessment

    In development [GID-HTE10041] Expected publication date: TBC

    Health technology evaluations
    In development

  28. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    Awaiting development [GID-TA11491] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  29. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development [GID-TA11326] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  30. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Awaiting development [GID-TA11396] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  31. Vamorolone for treating Duchenne muscular dystrophy [ID4024]

    In development [GID-TA11135] Expected publication date: TBC

    Technology appraisal guidance
    In development

  32. Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]

    In development [GID-TA10962] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  33. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

    In development [GID-TA10979] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  34. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued [GID-TA11124]

    Technology appraisal guidance
    Discontinued

  35. Linzagolix for treating pain caused by endometriosis [ID6357]

    In development [GID-TA11376] Expected publication date: TBC

    Technology appraisal guidance
    In development

  36. Targeted Muscle Reinnervation for refractory pain after limb amputation

    Awaiting development [GID-IPG10369] Expected publication date: 20 June 2025

    Interventional procedures guidance
    Awaiting development

  37. Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]

    In development [GID-TA11384] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  38. Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma ID6202

    In development [GID-TA11164] Expected publication date: TBC

    Technology appraisal guidance
    In development

  39. Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]

    In development [GID-TA11197] Expected publication date: TBC

    Technology appraisal guidance
    In development

  40. Serplulimab with chemotherapy for untreated extensive-stage small-cell lung cancer [ID6346]

    Awaiting development [GID-TA11405] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  41. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    In development [GID-TA11476] Expected publication date: TBC

    Technology appraisal guidance
    In development

  42. Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430

    Awaiting development [GID-TA11530] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  43. Zuranolone for treating severe postnatal depression ID6431

    Awaiting development [GID-TA11356] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  44. Teprotumumab for treating thyroid eye disease ID 6432

    Awaiting development [GID-TA11531] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  45. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  46. Artificial intelligence software to help detect fractures in the emergency department (provisional title)

    In development [GID-HTE10044] Expected publication date: 17 December 2024

    Health technology evaluations
    In development

  47. Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]

    In development [GID-TA10252] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  48. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    Awaiting development [GID-TA10895] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  49. Somapacitan for treating growth hormone deficiency in children [ID6178]

    In development [GID-TA11153] Expected publication date: TBC

    Technology appraisal guidance
    In development

  50. Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]

    In development [GID-TA11045] Expected publication date: 20 November 2024

    Technology appraisal guidance
    In development